MCID: CHR418
MIFTS: 47

Chronic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Chronic Leukemia

MalaCards integrated aliases for Chronic Leukemia:

Name: Chronic Leukemia 12 55 15 73
Adult Chronic Leukemia 12
Cll 12
Cml 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1036
NCIt 50 C3483
UMLS 73 C1279296

Summaries for Chronic Leukemia

Disease Ontology : 12 A leukemia that develops slowly.

MalaCards based summary : Chronic Leukemia, also known as adult chronic leukemia, is related to leukemia, chronic myeloid and leukemia, chronic lymphocytic. An important gene associated with Chronic Leukemia is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Focal Adhesion. The drugs Arzerra and Campath have been mentioned in the context of this disorder. Affiliated tissues include b cells, myeloid and bone marrow, and related phenotypes are Decreased sensitivity to paclitaxel and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Wikipedia : 76 Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is... more...

Related Diseases for Chronic Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Chronic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid 30.8 BCR STAT5B WT1
2 leukemia, chronic lymphocytic 29.8 ABCB4 ARL11 BCR CCND1
3 chronic myelomonocytic leukemia 11.5
4 leukemia 11.2
5 leukemia, t-cell, chronic 10.9
6 juvenile myelomonocytic leukemia 10.8
7 chronic neutrophilic leukemia 10.8
8 subacute leukemia 10.8
9 childhood leukemia 10.8
10 endometrial squamous cell carcinoma 10.2 CCND1 HGF
11 female reproductive endometrioid cancer 10.1 PTEN WT1
12 bowenoid papulosis 10.1 CCND1 PTGS2
13 keratocystic odontogenic tumor 10.0 CCND1 PTGS2
14 gastrointestinal system benign neoplasm 9.9 CCND1 PTGS2
15 synchronous bilateral breast carcinoma 9.8 CCND1 PTEN
16 intestinal benign neoplasm 9.8 CCND1 PTGS2
17 myelodysplastic syndrome 9.7
18 gastric ulcer 9.7 HGF PTGS2
19 bladder squamous cell carcinoma 9.7 HGF PTEN PTGS2
20 lymphoma 9.7
21 myeloid leukemia 9.7
22 myelofibrosis 9.6
23 myeloma, multiple 9.6
24 leukemia, acute myeloid 9.6
25 disseminated intravascular coagulation 9.6
26 b-cell growth factor 9.4
27 leukemia, chronic lymphocytic 2 9.4
28 wilms tumor 5 9.4
29 human herpesvirus 8 9.4
30 glucocorticoid resistance, generalized 9.4
31 wilms tumor 6 9.4
32 parotitis 9.4
33 prostatitis 9.4
34 lymphadenitis 9.4
35 richter's syndrome 9.4
36 myeloproliferative neoplasm 9.4
37 pneumonia 9.4
38 herpes zoster 9.4
39 lymphosarcoma 9.4
40 leukemia, b-cell, chronic 9.4
41 endotheliitis 9.4
42 gastrointestinal system cancer 9.4 CCND1 PTEN PTGS2
43 adamantinoma of long bones 9.3 CCND1 PTEN PTGS2
44 squamous cell carcinoma, head and neck 9.2 CCND1 PTEN PTGS2
45 cholangiocarcinoma 9.0 CCND1 HGF PTEN PTGS2
46 adenocarcinoma 8.9 CCND1 PTEN PTGS2
47 hematologic cancer 8.8 BCR CCND1 STAT5B WT1

Comorbidity relations with Chronic Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Chronic Leukemia:



Diseases related to Chronic Leukemia

Symptoms & Phenotypes for Chronic Leukemia

GenomeRNAi Phenotypes related to Chronic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 PTEN WT1
2 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 ABCB4 CCND1 PTEN

MGI Mouse Phenotypes related to Chronic Leukemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 STAT5B PTGS2 WT1 BCR PTEN CCND1
2 hematopoietic system MP:0005397 10.16 SOAT1 STAT5B WT1 CCND1 PTGS2 GFI1B
3 cardiovascular system MP:0005385 10.13 SOAT1 PTGS2 WT1 PTEN CCND1 GFI1B
4 homeostasis/metabolism MP:0005376 10.09 SOAT1 STAT5B PTGS2 WT1 BCR PTEN
5 growth/size/body region MP:0005378 10.08 STAT5B PTGS2 WT1 BCR PTEN CCND1
6 immune system MP:0005387 10.06 SOAT1 STAT5B WT1 PTEN CCND1 PTGS2
7 endocrine/exocrine gland MP:0005379 10.04 SOAT1 STAT5B PTGS2 WT1 PTEN CCND1
8 liver/biliary system MP:0005370 9.92 SOAT1 STAT5B WT1 PTGS2 ABCB4 HGF
9 integument MP:0010771 9.85 SOAT1 STAT5B PTGS2 PTEN CCND1 GFI1B
10 neoplasm MP:0002006 9.73 SOAT1 PTGS2 WT1 PTEN CCND1 ABCB4
11 normal MP:0002873 9.63 STAT5B PTGS2 WT1 BCR PTEN CCND1
12 renal/urinary system MP:0005367 9.35 WT1 STAT5B PTGS2 BCR PTEN
13 reproductive system MP:0005389 9.1 WT1 STAT5B PTGS2 PTEN CCND1 ABCB4

Drugs & Therapeutics for Chronic Leukemia

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
2
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
3
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
4
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
5
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
6
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
7
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Chronic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Not Applicable 220127-57-1 123596
8 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
10
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
11
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
13
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
14
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
15
alemtuzumab Approved, Investigational Phase 3,Phase 2 216503-57-0
16
Chlorambucil Approved Phase 3 305-03-3 2708
17
Dasatinib Approved, Investigational Phase 3,Phase 1,Phase 2 302962-49-8 3062316
18 Antimetabolites Phase 2, Phase 3,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1,Not Applicable
20 Antiemetics Phase 2, Phase 3
21 Anti-Inflammatory Agents Phase 2, Phase 3
22 Antilymphocyte Serum Phase 2, Phase 3,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 2, Phase 3
24 Autonomic Agents Phase 2, Phase 3
25 Calcineurin Inhibitors Phase 2, Phase 3,Phase 1
26 Gastrointestinal Agents Phase 2, Phase 3
27 glucocorticoids Phase 2, Phase 3
28 Hormone Antagonists Phase 2, Phase 3
29 Hormones Phase 2, Phase 3
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
31 Methylprednisolone acetate Phase 2, Phase 3
32 Methylprednisolone Hemisuccinate Phase 2, Phase 3
33 Neuroprotective Agents Phase 2, Phase 3
34 Peripheral Nervous System Agents Phase 2, Phase 3
35 Prednisolone acetate Phase 2, Phase 3
36 Prednisolone hemisuccinate Phase 2, Phase 3
37 Prednisolone phosphate Phase 2, Phase 3
38 Protective Agents Phase 2, Phase 3,Phase 1
39 tyrosine Nutraceutical Phase 3,Not Applicable
40
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
41
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
42
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
43
Cytarabine Approved, Investigational Phase 2,Not Applicable 147-94-4 6253
44
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
45
Thiotepa Approved, Investigational Phase 2,Not Applicable 52-24-4 5453
46 Mirabegron Approved Phase 2 223673-61-8 9865528
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Etoposide Approved Phase 2,Not Applicable 33419-42-0 36462
49
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
3 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
4 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
5 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
6 Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Completed NCT01511289 Phase 3 Imatinib;Radotinib
7 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
8 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
9 Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Recruiting NCT03079505 Phase 3 Dasatinib 100 MG [Sprycel];Nilotinib 150mg oral capsule [Tasigna]
10 A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Active, not recruiting NCT00471497 Phase 3 nilotinib;imatinib
11 Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. Terminated NCT02108951 Phase 3 Nilotinib
12 Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Terminated NCT00519090 Phase 3 Imatinib;Nilotinib (AMN107)
13 Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Unknown status NCT01472055 Phase 2 Fludarabine
14 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) Completed NCT00042016 Phase 2 decitabine (5-aza-2'deoxycytidine)
15 Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Completed NCT00002502 Phase 2 busulfan;cyclophosphamide;cytarabine
16 Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) Completed NCT01218477 Phase 1, Phase 2 Dasatinib;BMS-833923
17 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Completed NCT00378534 Phase 2 Fludarabine;Cyclosporine;Cyclophosphamide
18 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
19 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
20 Stem Cell Transplantation for Patients With Cancers of the Blood Completed NCT00467961 Phase 2
21 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation Completed NCT00859586 Phase 2
22 Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Completed NCT00074490 Phase 2 Rituximab;Fludarabine;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Filgrastim
23 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed NCT00079391 Phase 2
24 A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00073489 Phase 2 OSI-461
25 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00230282 Phase 2 Alemtuzumab;Fludarabine;Cytoxan
26 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Completed NCT01336712 Phase 2
27 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT01191190 Phase 2 Ofatumumab/HDMP
28 A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Completed NCT00431873 Phase 2 MGCD0103
29 Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy Recruiting NCT01521611 Phase 1, Phase 2
30 Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Recruiting NCT02169791 Phase 2 MLN9708
31 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
32 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Recruiting NCT01203722 Phase 1, Phase 2 Fludarabine, Cytoxan, TBI, Sirolimus + MMF;Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
33 Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR- Recruiting NCT02885766 Phase 1, Phase 2 PF-114
34 Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Terminated NCT01220297 Phase 2 Sirolimus;Mycophenolate mofetil (MMF);Carmustine;Etoposide;Cyclophosphamide (Cyclo, CY);FTBI
35 Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells Terminated NCT01624701 Phase 1, Phase 2
36 A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) Terminated NCT00076401 Phase 2 Motexafin gadolinium
37 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
38 Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer Completed NCT00005785 Phase 1 GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
39 Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Completed NCT00273936 Phase 1 AVN-944 capsules for oral administration
40 Umbilical Cord Blood Transplantation From Unrelated Donors Recruiting NCT03016806 Phase 1 Cyclophosphamide;Mesna;Busulfan;Fludarabine;Melphalan
41 A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia Terminated NCT00587457 Phase 1 CAT-8015 5 mcg/kg;CAT-8015 10 mcg/kg;CAT-8015 20 mcg/kg
42 Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias Completed NCT01144793
43 Fungemia in Hematologic Malignancies Completed NCT02451592
44 Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor Completed NCT01362985
45 Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia Completed NCT02520895
46 Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor Recruiting NCT02842333 Not Applicable
47 Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes Recruiting NCT02560883
48 Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) Recruiting NCT03469661
49 Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes Recruiting NCT00715247
50 Unrelated Donor Stem Cell Transplantation Recruiting NCT01364363 Not Applicable

Search NIH Clinical Center for Chronic Leukemia

Genetic Tests for Chronic Leukemia

Anatomical Context for Chronic Leukemia

MalaCards organs/tissues related to Chronic Leukemia:

41
B Cells, Myeloid, Bone Marrow, Bone, T Cells, Monocytes, Nk Cells

Publications for Chronic Leukemia

Articles related to Chronic Leukemia:

(show top 50) (show all 61)
# Title Authors Year
1
Cancer, Leukemia, Myeloid, Acute (AML, Erythroid Leukemia, Myelodysplasia-Related Leukemia, BCR-ABL Chronic Leukemia) ( 29939652 )
2018
2
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. ( 27229716 )
2016
3
Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients. ( 27511371 )
2016
4
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. ( 27579615 )
2016
5
Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. ( 27557388 )
2016
6
Your patient has chronic leukemia: Now what? ( 27505878 )
2016
7
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country. ( 27123350 )
2016
8
Antileukemic Effect of Tualang Honey on Acute and Chronic Leukemia Cell Lines. ( 26613081 )
2015
9
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 26107113 )
2015
10
Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report. ( 25985790 )
2015
11
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma. ( 26295844 )
2015
12
Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome. ( 24811835 )
2014
13
Analysis of the erythroid differentiation effect of flavonoid apigenin on K562 human chronic leukemia cells. ( 25058688 )
2014
14
Chronic leukemia. ( 24267282 )
2013
15
Exaggerated insect bite reaction related to chronic leukemia. ( 23541024 )
2013
16
Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy. ( 23936692 )
2013
17
Incidental diagnosis of a retroperitoneal schwannoma in a patient with chronic leukemia undergoing prostatic biopsy. ( 22760935 )
2012
18
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/I^-catenin function. ( 22708678 )
2012
19
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. ( 22547610 )
2012
20
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 22585692 )
2012
21
Prevalence of human herpesvirus 8 DNA in peripheral blood mononuclear cells of acute and chronic leukemia patients in Taiwan. ( 21392127 )
2011
22
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. ( 21678379 )
2011
23
Understanding and Targeting the Wnt/I^-Catenin Signaling Pathway in Chronic Leukemia. ( 23213540 )
2011
24
[Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells]. ( 22333553 )
2011
25
Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia. ( 21049055 )
2010
26
Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. ( 20376582 )
2010
27
Inhibition of cell growth by Stellera chamaejasme extract is associated with induction of autophagy and differentiation in chronic leukemia K562 cells. ( 20547324 )
2010
28
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. ( 19633691 )
2010
29
[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]. ( 20352702 )
2010
30
[Treatment of myeloproliferative neoplasms other than chronic leukemia]. ( 19860198 )
2009
31
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 19812383 )
2009
32
Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. ( 19360458 )
2009
33
Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. ( 18773885 )
2008
34
How I treat acute and chronic leukemia in pregnancy. ( 18472198 )
2008
35
PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. ( 16914202 )
2007
36
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). ( 17611571 )
2007
37
[Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance]. ( 17956662 )
2007
38
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. ( 17041886 )
2006
39
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. ( 16019534 )
2005
40
Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. ( 16084950 )
2005
41
TNR/11q#1 trinucleotide (GCC)n repeat alleles and predisposition to acute and chronic leukemia. ( 15225161 )
2004
42
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. ( 12007503 )
2002
43
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. ( 10676644 )
2000
44
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. ( 10979972 )
2000
45
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( 10828012 )
2000
46
Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part III: The chronic leukemias and myelofibrosis. ( 9553616 )
1997
47
Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias. ( 9407720 )
1997
48
Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. ( 9150348 )
1997
49
Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). ( 8769691 )
1996
50
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. ( 8656699 )
1996

Variations for Chronic Leukemia

Expression for Chronic Leukemia

Search GEO for disease gene expression data for Chronic Leukemia.

Pathways for Chronic Leukemia

GO Terms for Chronic Leukemia

Biological processes related to Chronic Leukemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.83 ABCB4 PTEN PTGS2 SOAT1
2 negative regulation of apoptotic process GO:0043066 9.8 HGF PTEN PTGS2 STAT5B WT1
3 positive regulation of cell proliferation GO:0008284 9.77 CCND1 HGF PTEN PTGS2 STAT5B
4 cytokine-mediated signaling pathway GO:0019221 9.76 CCND1 HGF PTGS2 STAT5B
5 response to drug GO:0042493 9.73 ABCB4 CCND1 PTEN PTGS2
6 response to lipopolysaccharide GO:0032496 9.71 ABCB4 BCR PTGS2
7 peptidyl-tyrosine phosphorylation GO:0018108 9.69 BCR HGF STAT5B
8 regulation of cell cycle GO:0051726 9.65 BCR CCND1 PTEN
9 response to organonitrogen compound GO:0010243 9.56 CCND1 PTGS2
10 platelet-derived growth factor receptor signaling pathway GO:0048008 9.55 BCR PTEN
11 lactation GO:0007595 9.5 ABCB4 CCND1 STAT5B
12 response to vitamin D GO:0033280 9.49 ABCB4 PTGS2
13 response to organic cyclic compound GO:0014070 9.46 ABCB4 CCND1 PTEN PTGS2
14 maintenance of permeability of blood-brain barrier GO:0035633 9.26 ABCB4 PTGS2
15 response to organic substance GO:0010033 9.26 ABCB4 CCND1 PTEN PTGS2
16 response to estradiol GO:0032355 9.02 ABCB4 CCND1 PTEN PTGS2 STAT5B

Molecular functions related to Chronic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.9 ABCB4 ARL11 BCR CCND1 GFI1B HGF
2 protein tyrosine kinase activity GO:0004713 9.13 BCR HGF STAT5B
3 enzyme binding GO:0019899 8.92 BCR CCND1 PTEN PTGS2

Sources for Chronic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....